LUMETTI, Federica
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.945
AS - Asia 4.661
EU - Europa 3.463
SA - Sud America 700
AF - Africa 117
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 7
Totale 15.909
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.760
SG - Singapore 1.452
CN - Cina 1.234
IT - Italia 947
GB - Regno Unito 777
BR - Brasile 538
HK - Hong Kong 523
VN - Vietnam 500
SE - Svezia 360
DE - Germania 282
FI - Finlandia 229
FR - Francia 195
KR - Corea 181
RU - Federazione Russa 171
IN - India 169
TR - Turchia 120
ID - Indonesia 116
UA - Ucraina 96
CA - Canada 89
MX - Messico 63
AR - Argentina 58
JP - Giappone 57
NL - Olanda 56
BG - Bulgaria 55
BD - Bangladesh 53
ES - Italia 51
PL - Polonia 46
ZA - Sudafrica 37
IQ - Iraq 36
AT - Austria 33
PK - Pakistan 31
IE - Irlanda 30
MY - Malesia 23
PE - Perù 22
MA - Marocco 21
BE - Belgio 18
CO - Colombia 17
IR - Iran 17
CL - Cile 16
CZ - Repubblica Ceca 16
EC - Ecuador 16
NO - Norvegia 16
RO - Romania 16
AE - Emirati Arabi Uniti 15
SA - Arabia Saudita 15
AU - Australia 14
LT - Lituania 13
TW - Taiwan 13
PY - Paraguay 12
TN - Tunisia 12
UZ - Uzbekistan 11
VE - Venezuela 11
EG - Egitto 10
KE - Kenya 9
AZ - Azerbaigian 8
CH - Svizzera 8
JO - Giordania 8
NP - Nepal 8
CR - Costa Rica 7
GR - Grecia 7
IL - Israele 7
TH - Thailandia 7
AL - Albania 6
BH - Bahrain 6
DO - Repubblica Dominicana 6
ET - Etiopia 6
HN - Honduras 6
HU - Ungheria 6
KZ - Kazakistan 6
PH - Filippine 6
PT - Portogallo 5
SY - Repubblica araba siriana 5
AO - Angola 4
BO - Bolivia 4
BY - Bielorussia 4
BZ - Belize 4
CY - Cipro 4
DK - Danimarca 4
DZ - Algeria 4
EU - Europa 4
GE - Georgia 4
KG - Kirghizistan 4
KH - Cambogia 4
RS - Serbia 4
AM - Armenia 3
BB - Barbados 3
LB - Libano 3
NG - Nigeria 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
UY - Uruguay 3
BA - Bosnia-Erzegovina 2
HR - Croazia 2
KW - Kuwait 2
LA - Repubblica Popolare Democratica del Laos 2
MD - Moldavia 2
ML - Mali 2
NZ - Nuova Zelanda 2
OM - Oman 2
PA - Panama 2
Totale 15.883
Salva come PNG Salva come JPEG
Città #
Santa Clara 952
Singapore 926
Ashburn 734
Hong Kong 516
San Jose 457
Fairfield 445
Southend 415
Chandler 414
Hefei 407
Woodbridge 251
London 199
Nyköping 190
Houston 188
Beijing 185
Ann Arbor 180
Seoul 169
Helsinki 166
Seattle 161
Wilmington 152
Jacksonville 150
Hanoi 146
Ho Chi Minh City 140
Cambridge 135
Council Bluffs 133
Los Angeles 133
The Dalles 129
Modena 116
Dearborn 109
New York 108
Jakarta 89
Chicago 88
San Diego 87
Bologna 75
Lauterbourg 73
Milan 71
Princeton 56
Shanghai 56
Izmir 54
Sofia 54
São Paulo 52
Moscow 48
Atlanta 46
Parma 46
Munich 45
Frankfurt am Main 43
Buffalo 40
Bremen 39
Orem 39
Tokyo 37
Warsaw 36
Rome 33
Salt Lake City 33
Dallas 31
Lappeenranta 28
Montreal 28
Delhi 27
Eugene 25
Denver 24
Guangzhou 23
Kent 23
Paris 23
Stockholm 23
Toronto 23
Da Nang 22
Florence 22
Haiphong 22
New Delhi 22
Columbus 21
Johannesburg 21
Valencia 21
Dublin 20
Redondo Beach 20
Reggio Emilia 20
Amsterdam 19
Chennai 19
Redwood City 19
Mexico City 17
Mumbai 17
Turin 17
Lima 16
Ottawa 16
Rio de Janeiro 16
Turku 16
Boardman 15
Brussels 15
Manchester 14
Phoenix 14
Baghdad 13
Brooklyn 13
Ovada 13
Poplar 13
Querétaro 13
Ankara 12
Elk Grove Village 12
Naples 12
Nuremberg 12
Pune 12
San Francisco 12
Skien 12
Belo Horizonte 11
Totale 10.525
Salva come PNG Salva come JPEG
Nome #
Systemic sclerosis progression INvestiGation (SPRING) Italian registry: Demographic and clinico-serological features of the scleroderma spectrum 400
Breast cancer in systemic sclerosis: Results of a cross-linkage of an Italian Rheumatologic Center and a population-based Cancer Registry and review of the literature 333
Cardio-pulmonary disease management in patients with systemic sclerosis: cardio-rheumatology clinic and patient care standardisation proposal 319
Established coronary artery disease in systemic sclerosis compared to type 2 diabetic female patients: a cross-sectional study 318
Serum 25-OH vitamin D levels in systemic sclerosis: analysis of 140 patients and review of the literature 317
Cardiac involvement in systemic sclerosis: identification of high-risk patient profiles in different patterns of clinical presentation 316
Cryoglobulinemic vasculitis and skin ulcers. Our therapeutic strategy and review of the literature 300
APPLICATION OF CRITERIA FOR THE DIAGNOSIS OF “CLINICAL OSTEOPOROSIS ” IN A POPULATION OF POSTMENOPAUSAL WOMEN FROM EMILIA-ROMAGNA REGION 291
Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline 289
Long-term treatment with rituximab in interstitial lung disease related to systemic sclerosis: our clinical experience 280
Diagnosis and treatment of rheumatoid arthritis in the Emilia Romagna region: a prospective population-based study 275
Management of cardiopulmonary disease in patients with systemic sclerosis: cardiorheumatology clinic and patient care standardization proposal 272
Beyond cat scratch disease: a case report of bartonella infection mimicking vasculitic disorder 265
Use of Neem oil and Hypericum perforatum for treatment of calcinosis-related skin ulcers in systemic sclerosis 252
Autologous Fat Grafting for the Oral and Digital Complications of Systemic Sclerosis: Results of a Prospective Study 248
Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature 245
Advanced oxidation protein products in serum of patients with systemic sclerosis: a possible indicator of clinical evolution 244
COMPLEMENT DEPLETION IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOCILIZUMAB: A MARKER OF CLINICAL EFFICACY? 244
Scleroderma Digital Ulcers Complicated by Infection with Fecal Pathogens. 238
RETENTION RATE OF ADALIMUMAB AND ABP 501 IN THE TREATMENT OF A LARGE COHORT OF PATIENTS WITH INFLAMMATORY ARTHRITIS: A REAL LIFE RETROSPECTIVE ANALYSIS 233
A SELF-ADMINISTERED QUESTIONNAIRE MAY ALLOW GENERAL PRACTITIONERS TO PERFORM A RAPID SCREENING TO IDENTIFY PATIENTS AT RISK FOR FRAGILITY FRACTURES AND TO ADDRESS THEM TO BONE METABOLISM SPECIALIZED CLINICAL CENTERS 231
Adalimumab and ABP 501 in the Treatment of a Large Cohort of Patients with Inflammatory Arthritis: A Real Life Retrospective Analysis 231
Photobiomodulation Therapy: A New Light in the Treatment of Systemic Sclerosis Skin Ulcers 228
Osteomyelitis complicating scleroderma digital ulcers. 225
AB0611 STRAIN ANALYSIS OF THE RIGHT VENTRICLE USING 2D-SPECKLE TRACKING ECHOCARDIOGRAPHY IN A COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS 224
Assessing hand grasp in patients with systemic sclerosis using the 16-grasp test: Preliminary results from a multidisciplinary study group 222
SEVERE VITAMIN D DEFICIENCY IN SYSTEMIC SCLEROSIS 215
DIGITAL NECROSIS IN SYSTEMIC SCLEROSIS NOT ONLY A MICROVASCULAR DISEASE: A CASE REPORT 213
Invited Response on: Comments on "Autologous Fat Grafting for the Oral and Digital Complications of Systemic Sclerosis: Results of a Prospective Study" 213
COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study 212
Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study 205
The predictive role of the TAPSE/sPAP ratio for cardiovascular events and mortality in systemic sclerosis with pulmonary hypertension 200
AB0724 Cardio-pulmonary disease management in patients with systemic sclerosis: cardio-rheumatology clinic and patient care standardisation proposal 198
Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments 196
Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study (2023-02-07) 194
Thu0349 autologous fat grafting in the treatment of patients with systemic sclerosis: current experience and future prospects 194
AB0645 CANNABINOIDS IN THE TREATMENT OF PAIN RELATED TO SYSTEMIC SCLEROSIS SKIN ULCERS: OUR EXPERIENCE 194
Scleroderma skin ulcers definition, classification and treatment strategies our experience and review of the literature 193
AB0760 Advanced oxidation protein products in serum of patients with systemic sclerosis: a possible indicator of clinical evolution 193
Predictive Value of DLCO Reduction in Scleroderma Patients Without Cardio-Pulmonary Involvement at Baseline 189
Promising use of filgotinib in patients affected by systemic sclerosis: Preliminary data from a case series of 5 patients 187
Baseline Ultrasound Assessment Improves the Response to Apremilast in Patients with Psoriatic Arthritis: Results from a Multicentre Study 186
Molecular Pathways of Breast Cancer in Systemic Sclerosis: Exploratory Immunohistochemical Analysis from the Sclero-Breast Study 184
Overall mortality in combined pulmonary fibrosis and emphysema related to systemic sclerosis 182
AB0212 LONG-TERM TREATMENT WITH RITUXIMAB IN SYSTEMIC SCLEROSISMANAGEMENT: AN OVERVIEW OF THE CLINICAL EXPERIENCE FROM A REAL-LIFE SETTING 181
One-year clinical experience on the use of Nintedanib in Systemic Sclerosis 180
Altered pathways of keratinization, extracellular matrix generation, angiogenesis, and stromal stem cells proliferation in patients with systemic sclerosis 178
Treatment with Rituximab in Systemic Sclerosis Patients: Our Experience in a Pilot Clinical Trial 177
EFFICACY OF CERTOLIZUMAB PEGOL FOR DISEASE CONTROL OF PATIENTS AFFECTED BY ENTEROPATHIC SPONDYLARTHRITIS FOLLOWED BY THE JOINT GASTRO-RHEUMATOLOGICAL CLINIC 175
THU0600 a case of systemic sclerosis complicated by renal crisis: potential etiopathogenetic role of cytomegalovirus and treatment 173
Efficacy and Drug Survival after Switching from Etanercept to the Biosimilar SB4: A Real-Life Long-Term Study 173
From Localized Scleroderma to Systemic Sclerosis: Coexistence or Possible Evolution 166
A CALL FOR A COMPREHENSIVE ROLE DEFINITION OF THE STUDY COORDINATOR IN RHEUMATOLOGICAL CLINICAL STUDIES 160
Long-term treatment of scleroderma-related digital ulcers with iloprost: a cohort study 158
PROBABILITÀ DI SIEROCONVERSIONE DEL TEST QUANTIFERON DURANTE LA TERAPIA BIOTECNOLOGICA: DATI PRELIMINARI DI UNO STUDIO RETROSPETTIVO CONDOTTO PRESSO L’ARTHRITIS CLINIC DELL’AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO DI MODENA 156
ACCERTAMENTO DELLA DISABILITÀ NELLE MALATTIE REUMATOLOGICHE (EX L.R. N.4 DEL 19 FEBBRAIO 2008) PROPOSTA DI PROTOCOLLO ORGANIZZATIVO 156
KIENBOCK DISEASE IN A PATIENT WITH SSc: A CASE REPORT 154
PSYCHIATRIC DISORDERS IN RHEUMATOLOGY: EVALUATION OF A SCREENING PROTOCOL IN 100 HOSPITALIZED PATIENTS 154
SAT0285 EVALUATION OF CHRONIC PAIN IN PATIENTS WITH SYSTEMIC SCLEROSIS COMPARED TO THOSE WITH CHRONIC HEADACHE AND RHEUMATOID ARTHRITIS 151
A New Promising Role for Selexipag in the Treatment of Scleroderma Vasculopathy: Preliminary Results From a Third Level Italian Scleroderma Center 141
Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology 138
FRI0442 Long-term treatment with rituximab in interstitial lung disease related to systemic sclerosis: our clinical experience 135
CONFRONTO TRA STRATEGIE DI TERAPIA AVANZATA DI 2° E 3° LINEA NELLA ARTRITE PSORIASICA: RISULTATI PRELIMINARI DALLO STUDIO OSSERVAZIONE RETROSPETTIVO BIRRA 134
Erratum: From Localized Scleroderma to Systemic Sclerosis: Coexistence or Possible Evolution (Dermatology Research and Practice (2018) 2018 (1284687) DOI: 10.1155/2018/1284687) 132
Real life use of prostacyclin analog (Iloprost), a multi-centric survey data from the scleroderma study group Emilia Romagna (Sclero-RER) and review of the literature 131
CYCLING VS SWAP TNFi AND IL17i IN PSORIATIC ARTHRITIS: RESULTS FROM THE BIRRA RETROSPECTIVE OBSERVATIONAL STUDY 125
L’IPERTENSIONE POLMONARE: DALLE NUOVE LINEE GUIDA ALLA PRATICA CLINICA 125
DIFFERENCES BETWEEN SELECTIVE AND UNSELECTIVE JAKi: RESULTS FROM A MULTICENTRIC, REAL LIFE STUDY CARRIED OUT ON PATIENTS WITH RA 120
Cycling versus swapping strategieswith TNF-α inhibitors and IL-17 inhibitors in psoriatic arthritis in clinical practice 118
POS0604 JAKi’S SURVIVAL RATE AND PREDICTORS OF DISCONTINUATION IN A COHORT OF PATIENTS WITH RHEUMATOID ARTHRITIS 117
Infections of scleroderma digital ulcers: A single center cohort retrospective study 116
Effectiveness and Predictors of Long-Term Treatment Response to Tofacitinib in Rheumatoid Arthritis Cohort: General Analysis and Focus on High-Cardiovascular-Risk Subgroup— AMulticenter Study 105
OP0063 QUANTITATIVE COMPUTED TOMOGRAPHY PREDICTS 10-YEAR MORTALITY IN INTERSTITIAL LUNG DISEASE RELATED TO SYSTEMIC SCLEROSI 102
Influence of safety warnings on the prescribing attitude of JAK 2inhibitors for rheumatoid arthritis in Italy 100
Multicenter observational study on the efficacy of selective Janus Kinase-1 inhibitor upatacitinib in rheumatoid arthritis 100
Prevalence and clinical relevance of digital ulcers in systemic sclerosis patients from the real-life: the experience of the SPRING Registry of the Italian Society for Rheumatology 94
Pulmonary Arterial Hypertension Incidence in Patients With Systemic Sclerosis Treated With Bosentan for Digital Ulcers: Evidence From the SPRING-SIR Registry. 93
Long-Term Retention Rate of Tofacitinib in Rheumatoid Arthritis: An Italian Multicenter Retrospective Cohort Study 89
Ixekizumab Retention Rate and Predictors of Treatment Persistence in Psoriatic Arthritis: Results of an Italian Multicenter Study 89
FRI0651 Quantitative chest ct predicts 8-years-mortality and comorbidity in systemic sclerosis 89
Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase 86
First-line diagnostic tests to intercept primary heart involvement in systemic sclerosis: Clinical associations from the SPRING-SIR registry 77
Therapeutic Effects of Apremilast on Enthesitis and Dactylitis in Real Clinical Setting: An Italian Multicenter Study 73
MYCOPHENOLATE MOFETIL TREATMENT REDUCES THE RISK OF TREATMENT ESCALATION DUE TO VASCULAR COMPLICATIONS IN LIMITED CUTANEOUS SYSTEMIC SCLEROSIS: EMULATION OF A TARGET TRIAL FROM ITALIAN RHEUMATOLOGY SOCIETY SPRING REGISTRY 59
Elderly-onset systemic sclerosis defines a distinct clinical subset: analysis from the SPRING registry of the Italian Society for Rheumatology 55
Comparative effectiveness of cycling versus swapping to UL-17 inhibitors after first TNF inhibitor failure in Psoriatic Arthritis: A real- world multicenter study 45
Menopause in systemic sclerosis: the impact on clinical presentation in a multicenter cross-sectional analysis from the National Registry of the Italian Society for Rheumatology (SPRING-SIR) 41
Gastrointestinal involvement in very early and established systemic sclerosis: insights from the SPRING-SIR national Italian registry. 39
Guselkumab effectiveness in real-world settings: Observations from an Italian multicentre study 30
Prevalence, distribution and associations of the scleroderma capillaroscopic patterns: new insights from the Italian SPRING-SIR registry 23
Does Prior Exposure Affect Retention? A Real‑World, Multicentre Assessment of IL‑17 Inhibitor Cycling in Psoriatic Arthritis 23
Age and onset timing of Raynaud’s phenomenon and first non-Raynaud symptom as prognostic factors in systemic sclerosis: a retrospective analysis from the Italian national multicenter Systemic Sclerosis Progression INvestiGation registry of the Italian Society for Rheumatology (SPRING-SIR) 21
Filgotinib Effectiveness in Rheumatoid Arthritis: Observational Analysis of a Large Multicenter Cohort 20
Exploring Disease-Specific Risk Factors for Vertebral Fractures in Systemic Sclerosis: Insights from the ScleroRER Study Group 15
Totale 16.080
Salva come PNG Salva come JPEG
Categoria #
all - tutte 60.723
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 60.723
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021262 0 0 0 0 0 0 0 0 0 110 109 43
2021/20221.160 31 45 86 100 47 88 42 91 150 95 243 142
2022/20231.261 157 147 89 114 127 160 51 119 177 19 51 50
2023/2024970 27 61 47 143 196 55 84 98 23 33 74 129
2024/20253.728 121 52 64 233 740 599 313 198 428 145 343 492
2025/20266.322 482 272 520 909 947 500 898 386 701 707 0 0
Totale 16.080